Cargando…
Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial
BACKGROUND: Risedronate increases bone mineral density (BMD) and reduces fracture risk, but treatment response may depend on the baseline state of bone turnover. Data regarding the selection of therapeutic drugs or the prediction of therapeutic effects with baseline levels of bone turnover markers (...
Autores principales: | Mawatari, Taro, Ikemura, Satoshi, Matsui, Gen, Iguchi, Takahiro, Mitsuyasu, Hiroaki, Kawahara, Shinya, Maehara, Masayuki, Muraoka, Ryoichi, Iwamoto, Yukihide, Nakashima, Yasuharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240327/ https://www.ncbi.nlm.nih.gov/pubmed/32462056 http://dx.doi.org/10.1016/j.bonr.2020.100275 |
Ejemplares similares
-
Brown Tumor of the Patella Caused by Primary Hyperparathyroidism: A Case Report
por: Irie, Tomoko, et al.
Publicado: (2015) -
Spontaneous bilateral femoral neck fractures in a young male adult: a case report and literature review
por: Arisumi, Shinkichi, et al.
Publicado: (2019) -
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials
por: Mawatari, T., et al.
Publicado: (2016) -
Improved surgical procedure of primary constrained total knee arthroplasty which enables use of the femoral diaphyseal straight extension stem
por: Kawahara, Shinya, et al.
Publicado: (2022) -
Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)